The Cooper Companies, Inc. (COO)
How Much Upside is Left in The Cooper Companies (COO)? Wall Street Analysts Think 26.47%
The consensus price target hints at a 26.5% upside potential for The Cooper Companies (COO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cooper Companies Likely to Beat Q3 Earnings Estimate on Lens Demand
COO's Q3 results may top estimates, powered by strong demand for MyDay lenses, Biofinity gains and surgical product resilience despite fertility softness.
The Cooper Companies (COO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for The Cooper Companies (COO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2025.
The Cooper Companies (COO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
The Cooper Companies (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cooper Companies' Innovation Fuels Growth Amid Macro Headwinds
COO leans on innovation and diversification to fuel growth, but fertility softness, tariffs and inventory headwinds weigh on near-term outlook.
All You Need to Know About The Cooper Companies (COO) Rating Upgrade to Buy
The Cooper Companies (COO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
COO or SAUHY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either The Cooper Companies (COO) or Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?
COO Stock Declines Despite Strong Core Growth Amid Fertility Woes
The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.
Medicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studies
Medicus Pharma (NASDAQ:MDCX) said on Monday it has appointed Andrew Smith as chief operating officer, bringing on board a seasoned asset management executive as the company accelerates its clinical development programs in the US, Europe, and the Middle East. Smith, who most recently served as CEO of SR Asset Management until its sale in 2024, brings over 30 years of experience in financial and operational leadership.
3 Oversold Stocks Flashing Bullish Reversal Signals
When it comes to short-term trading signals, few indicators are as closely tracked as the Relative Strength Index (RSI). A stock's RSI measures the speed and magnitude of its recent price movements.
Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Understanding The Cooper Companies (COO) Reliance on International Revenue
Explore The Cooper Companies' (COO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
